Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for VIVUS, Inc. (VVUSQ : OTC)

• Company Description    VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead investigational product in clinical development, Qnexa(TM), is expected to complete Phase 3 clinical trials for the treatment of obesity in 2009. Qnexa is also in Phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in Phase 3 development with avanafil, its PDE5 inhibitor drug candidate, and in Phase 2 development of Luramist(TM), its drug candidate for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $ Daily Weekly Monthly 20 Day Moving Average: shares Shares Outstanding: (millions) Market Capitalization: $ (millions) Beta: 52 Week High: $0.50 52 Week Low: $0.07 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week % % 12 Week % % Year To Date % %

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 900 E. HAMILTON AVENUE SUITE 550 - CAMPBELL,CA 95008 USA ph: 650-934-5200 fax: 650-934-5389 ir@vivus.com http://www.vivus.com

• General Corporate Information    Officers John P. Amos - Chief Executive Officer and Director David Y. Norton - Chairman of the Board of Directors Mark K. Oki - Senior Vice President; Chief Financial Officer and Karen Ferrell - Director Edward A. Kangas - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 928551308 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: Most Recent Split Date: 9.00 (0.10:1) Beta: Market Capitalization: $ (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: % Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/25 - - 12/31/24 - - 09/30/24 - - ROA 03/31/25 - - 12/31/24 - - 09/30/24 - - Current Ratio 03/31/25 - - 12/31/24 - - 09/30/24 - - Quick Ratio 03/31/25 - - 12/31/24 - - 09/30/24 - - Operating Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Net Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Pre-Tax Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Book Value 03/31/25 - - 12/31/24 - - 09/30/24 - - Inventory Turnover 03/31/25 - - 12/31/24 - - 09/30/24 - - Debt-to-Equity 03/31/25 - - 12/31/24 - - 09/30/24 - - Debt-to-Capital 03/31/25 - - 12/31/24 - - 09/30/24 - -

Powered by Zacks Investment Research ©